Complex adenovirus-mediated expression of West Nile Virus C, preM, E, and NS1 proteins induces both humoral and cellular immune responses

Jennifer Schepp-Berglind, Min Luo, Danher Wang, Jason A. Wicker, Nicholas U. Raja, Brian D. Hoel, David H. Holman, Alan Barrett, John Y. Dong

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

West Nile Virus (WNV), a member of the family Flaviviridae, was first identified in Africa in 1937. In recent years, it has spread into Europe and North America. The clinical manifestations of WNV infection range from mild febrile symptoms to fatal encephalitis. Two genetic lineages (lineages I and II) are recognized; lineage II is associated with mild disease, while lineage I has been associated with severe disease, including encephalitis. WNV has now spread across North America, significantly affecting both public and veterinary health. In the efforts to develop an effective vaccine against all genetic variants of WNV, we have studied the feasibility of inducing both neutralizing and cellular immune responses by de novo synthesis of WNV antigens using a complex adenoviral vaccine (CAdVax) vector. By expressing multiple WNV proteins from a single vaccine vector, we were able to induce both humoral and cellular immune responses in vaccinated mice. Neutralization assays demonstrated that the antibodies were broadly neutralizing against both lineages of WNV, with a significant preference for the homologous lineage II virus. The results from this study show that multiple antigens synthesized de novo from a CAdVax vector are capable of inducing both humoral and cellular immune responses against WNV and that a multiantigen approach may provide broad protection against multiple genetic variants of WNV.

Original languageEnglish (US)
Pages (from-to)1117-1126
Number of pages10
JournalClinical and Vaccine Immunology
Volume14
Issue number9
DOIs
StatePublished - Sep 2007

Fingerprint

West Nile virus
Humoral Immunity
Viruses
Adenoviridae
Cellular Immunity
Proteins
Vaccines
Encephalitis
North America
Flaviviridae
Antigens
Virus Diseases
Fever
Public Health
Assays
Health
Antibodies

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

Complex adenovirus-mediated expression of West Nile Virus C, preM, E, and NS1 proteins induces both humoral and cellular immune responses. / Schepp-Berglind, Jennifer; Luo, Min; Wang, Danher; Wicker, Jason A.; Raja, Nicholas U.; Hoel, Brian D.; Holman, David H.; Barrett, Alan; Dong, John Y.

In: Clinical and Vaccine Immunology, Vol. 14, No. 9, 09.2007, p. 1117-1126.

Research output: Contribution to journalArticle

Schepp-Berglind, Jennifer ; Luo, Min ; Wang, Danher ; Wicker, Jason A. ; Raja, Nicholas U. ; Hoel, Brian D. ; Holman, David H. ; Barrett, Alan ; Dong, John Y. / Complex adenovirus-mediated expression of West Nile Virus C, preM, E, and NS1 proteins induces both humoral and cellular immune responses. In: Clinical and Vaccine Immunology. 2007 ; Vol. 14, No. 9. pp. 1117-1126.
@article{ce0ace9d62c3491aa762385142450339,
title = "Complex adenovirus-mediated expression of West Nile Virus C, preM, E, and NS1 proteins induces both humoral and cellular immune responses",
abstract = "West Nile Virus (WNV), a member of the family Flaviviridae, was first identified in Africa in 1937. In recent years, it has spread into Europe and North America. The clinical manifestations of WNV infection range from mild febrile symptoms to fatal encephalitis. Two genetic lineages (lineages I and II) are recognized; lineage II is associated with mild disease, while lineage I has been associated with severe disease, including encephalitis. WNV has now spread across North America, significantly affecting both public and veterinary health. In the efforts to develop an effective vaccine against all genetic variants of WNV, we have studied the feasibility of inducing both neutralizing and cellular immune responses by de novo synthesis of WNV antigens using a complex adenoviral vaccine (CAdVax) vector. By expressing multiple WNV proteins from a single vaccine vector, we were able to induce both humoral and cellular immune responses in vaccinated mice. Neutralization assays demonstrated that the antibodies were broadly neutralizing against both lineages of WNV, with a significant preference for the homologous lineage II virus. The results from this study show that multiple antigens synthesized de novo from a CAdVax vector are capable of inducing both humoral and cellular immune responses against WNV and that a multiantigen approach may provide broad protection against multiple genetic variants of WNV.",
author = "Jennifer Schepp-Berglind and Min Luo and Danher Wang and Wicker, {Jason A.} and Raja, {Nicholas U.} and Hoel, {Brian D.} and Holman, {David H.} and Alan Barrett and Dong, {John Y.}",
year = "2007",
month = "9",
doi = "10.1128/CVI.00070-07",
language = "English (US)",
volume = "14",
pages = "1117--1126",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Complex adenovirus-mediated expression of West Nile Virus C, preM, E, and NS1 proteins induces both humoral and cellular immune responses

AU - Schepp-Berglind, Jennifer

AU - Luo, Min

AU - Wang, Danher

AU - Wicker, Jason A.

AU - Raja, Nicholas U.

AU - Hoel, Brian D.

AU - Holman, David H.

AU - Barrett, Alan

AU - Dong, John Y.

PY - 2007/9

Y1 - 2007/9

N2 - West Nile Virus (WNV), a member of the family Flaviviridae, was first identified in Africa in 1937. In recent years, it has spread into Europe and North America. The clinical manifestations of WNV infection range from mild febrile symptoms to fatal encephalitis. Two genetic lineages (lineages I and II) are recognized; lineage II is associated with mild disease, while lineage I has been associated with severe disease, including encephalitis. WNV has now spread across North America, significantly affecting both public and veterinary health. In the efforts to develop an effective vaccine against all genetic variants of WNV, we have studied the feasibility of inducing both neutralizing and cellular immune responses by de novo synthesis of WNV antigens using a complex adenoviral vaccine (CAdVax) vector. By expressing multiple WNV proteins from a single vaccine vector, we were able to induce both humoral and cellular immune responses in vaccinated mice. Neutralization assays demonstrated that the antibodies were broadly neutralizing against both lineages of WNV, with a significant preference for the homologous lineage II virus. The results from this study show that multiple antigens synthesized de novo from a CAdVax vector are capable of inducing both humoral and cellular immune responses against WNV and that a multiantigen approach may provide broad protection against multiple genetic variants of WNV.

AB - West Nile Virus (WNV), a member of the family Flaviviridae, was first identified in Africa in 1937. In recent years, it has spread into Europe and North America. The clinical manifestations of WNV infection range from mild febrile symptoms to fatal encephalitis. Two genetic lineages (lineages I and II) are recognized; lineage II is associated with mild disease, while lineage I has been associated with severe disease, including encephalitis. WNV has now spread across North America, significantly affecting both public and veterinary health. In the efforts to develop an effective vaccine against all genetic variants of WNV, we have studied the feasibility of inducing both neutralizing and cellular immune responses by de novo synthesis of WNV antigens using a complex adenoviral vaccine (CAdVax) vector. By expressing multiple WNV proteins from a single vaccine vector, we were able to induce both humoral and cellular immune responses in vaccinated mice. Neutralization assays demonstrated that the antibodies were broadly neutralizing against both lineages of WNV, with a significant preference for the homologous lineage II virus. The results from this study show that multiple antigens synthesized de novo from a CAdVax vector are capable of inducing both humoral and cellular immune responses against WNV and that a multiantigen approach may provide broad protection against multiple genetic variants of WNV.

UR - http://www.scopus.com/inward/record.url?scp=34948848718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948848718&partnerID=8YFLogxK

U2 - 10.1128/CVI.00070-07

DO - 10.1128/CVI.00070-07

M3 - Article

C2 - 17634508

AN - SCOPUS:34948848718

VL - 14

SP - 1117

EP - 1126

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 9

ER -